Jardiance

(Empagliflozin)

ApprovedSmall molecule

Empagliflozin is used to treat type 2 diabetes by helping the kidneys remove excess sugar through urine, and it also helps protect the heart and kidneys in patients with diabetes or heart disease.[2] Jardiance is currently approved and in use across 77 indications[4].[1]

Jardiance is one of 1113 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

Indications

416

Total Trials

Active Trials

1,112

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Coronary Artery DiseaseUnknown status

Metabolic SyndromeEnrolling by invitation

Glycogen Storage Disease Due to Glucose-6-Phosphatase Deficiency Type IAApproved

Hepatic FailureApproved

Endothelial DysfunctionNot yet recruiting

Diabetic KetoacidosisActive, not recruiting

Inappropriate ADH SyndromeApproved

AlbuminuriaActive, not recruiting

Mitral RegurgitationActive, not recruiting

Ischemia Reperfusion InjuryActive, not recruiting

Coronary Artery DiseaseApproved

Unknown status

Metabolic SyndromePhase 3

Enrolling by invitation

Glycogen Storage Disease Due to Glucose-6-Phosphatase Deficiency Type IAApproved

Approved

Hepatic FailureApproved

Approved

Endothelial DysfunctionApproved

Not yet recruiting

Diabetic KetoacidosisPreclinical

Active, not recruiting

Inappropriate ADH SyndromeApproved

Approved

AlbuminuriaApproved

Active, not recruiting

Mitral RegurgitationPreclinical

Active, not recruiting

Ischemia Reperfusion InjuryPreclinical

Active, not recruiting

Showing 10 of 76 indications

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Approved

2 2

Lexiscan

Astellas

Preclinical

1 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

Chantix

PPrism Pharmaceuticals

Preclinical

1 5

Rilvegostomig

AstraZeneca

Preclinical

1 6

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 7

Tianeptine

Pfizer

Preclinical

1 8

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 9

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 10

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Pulmonary Arterial Hypertension

NCT06554301

Post-ApprovalNot yet recruiting

Type 2 Diabetes Mellitus

NCT07311551

Phase 3Recruiting

Schizophrenia

NCT05669742

Phase 2/3Recruiting

Cardiorenal Syndrome Type 1

NCT06030843

Q1 2027

Phase 2Recruiting

Heart Failure

NCT07372040

N/ARecruiting

Sepsis

NCT06473844

Clinical

Trials by Indication[1]

Empagliflozin55 trials

Empagliflozin and Hepatic Glucose Metabolism

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT03193684·72 enrolled

Effect of Empagliflozin on Inflammation

Recruiting·HHotel Dieu de France Hospital·Phase 4·NCT07292909·100 enrolled

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

Completed·—·N/A·NCT06313008·120 enrolled

Show 52 more trials

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Terminated·IIntarcia Therapeutics·Phase 3·NCT03060980·245 enrolled

Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.

Completed· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·N/A·NCT03771781·48 enrolled

Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

Unknown status·—··NCT06284850·40 enrolled

Effect of Empagliflozin on Ventricular Repolarization.

Completed·UUniversity of Sao Paulo·Phase 4·NCT04117763·90 enrolled

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy

Unknown status·—··NCT05103306·300 enrolled

Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg

Unknown status·BBio-innova Co., Ltd·Phase 1·NCT06232239·26 enrolled

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Completed·GGedeon Richter Plc.·Phase 1·NCT06792968·64 enrolled

Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07372118·32 enrolled

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01975220·72 enrolled

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07213895·14 enrolled

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Completed·DDong-A ST Co., Ltd.·Phase 1·NCT03766724·42 enrolled

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Completed·GGenuine Research Center, Egypt·Phase 1·NCT05132023·26 enrolled

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02106923·72 enrolled

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02758171·56 enrolled

Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin

Unknown status·—·Phase 2/3·NCT06103279·40 enrolled

Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

Completed·—·Phase 3·NCT05036421·18 enrolled

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Completed·HHandok Inc.·Phase 1·NCT06889350·40 enrolled

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04295005·24,500 enrolled

The Effects of Empagliflozin on Arterial Wall Characteristics

Unknown status·UUniversity Medical Centre Ljubljana·Phase 4·NCT03639545·120 enrolled

Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

Unknown status·SSeoul National University Bundang Hospital·Phase 4·NCT05140694·135 enrolled

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT03429543·175 enrolled

Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics

Unknown status·—·Phase 4·NCT01001962·1,054 enrolled

Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07266766·40 enrolled

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02230995·30 enrolled

Empagliflozin in ESKD - A Feasibility Study

Recruiting·UUniversity of Mississippi Medical Center·Phase 1/2·NCT05687058·24 enrolled

Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT06932159·40 enrolled

Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions

Completed·MMutah University·N/A·NCT05229796·26 enrolled

Drug Interaction Study Between Dorzagliatin and Empagliflozin

Completed·HHua Medicine Limited·Phase 1·NCT03790787·16 enrolled

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01867307·39 enrolled

Emp-Activity: Empagliflozin Functional Capacity

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05350202·3,431 enrolled

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02632747·31 enrolled

Pharmacokinetic Evaluation of Empagliflozin

Completed·—·Phase 1·NCT03059056·6 enrolled

Characteristics of Empagliflozin Initiators

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03050619·31,908 enrolled

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Completed·GGedeon Richter Plc.·Phase 1·NCT06766500·64 enrolled

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02266472·30 enrolled

Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

Completed·PProfil Institut für Stoffwechselforschung GmbH·Phase 4·NCT02401880·89 enrolled

Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02577315·25 enrolled

Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

Active, not recruiting·CConrado Roberto Hoffmann Filho·Phase 3·NCT06683053·90 enrolled

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Completed·GGedeon Richter Plc.·Phase 1·NCT06823856·64 enrolled

Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01672788·36 enrolled

Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01811953·48 enrolled

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

Completed·HHandok Inc.·Phase 1·NCT04431141·32 enrolled

Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01844531·24 enrolled

Empagliflozin vs Metformin in PCOS

Completed·HHull University Teaching Hospitals NHS Trust·Phase 2/3·NCT03008551·40 enrolled

Empagliflozin and Cardiac Remodelling in People Without Diabetes

Completed·UUnity Health Toronto·Phase 4·NCT04461041·169 enrolled

Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).

Completed·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT03485222·84 enrolled

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Completed·HHandok Inc.·Phase 1·NCT06339788·40 enrolled

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Completed·—··NCT03748810·600 enrolled

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

Recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT07331389·111 enrolled

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03259490·30 enrolled

A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05083949·32 enrolled

Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study

Completed·UUniversity Hospital, Basel, Switzerland·Phase 2/3·NCT02874807·88 enrolled

Type 2 Diabetes Mellitus17 trials

Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Not yet recruiting· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 4·NCT07365358·200 enrolled

Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05130463·1,053 enrolled

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02453555·275 enrolled

Show 14 more trials

A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)

Not yet recruiting·—·Phase 4·NCT07311551·112 enrolled

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01649297·983 enrolled

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02182830·166 enrolled

Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus

Unknown status·CCentro Universitario de Ciencias de la Salud, Mexico·Phase 3·NCT04195243·24 enrolled

Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus

Completed·—·Phase 3·NCT06952231·50 enrolled

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

Completed·LLexicon Pharmaceuticals·Phase 3·NCT03351478·770 enrolled

To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05162014·494,679 enrolled

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02121483·27 enrolled

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Terminated· Novartis logo

Novartis·Phase 2·NCT03152552·125 enrolled

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02489968·880 enrolled

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03249506·25,358 enrolled

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT04014192·40 enrolled

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03492580·714,582 enrolled

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02863328·822 enrolled

Heart Failure14 trials

The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure

Completed·JJacob Moller·Phase 2·NCT05084235·191 enrolled

EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction

Unknown status·ZZhijun Sun·Phase 4·NCT05584319·100 enrolled

Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

Unknown status·—·Phase 2·NCT06012266·12 enrolled

Show 11 more trials

Empagliflozin in Heart Failure Dialysis Patients

Completed·SShahid Beheshti University of Medical Sciences·N/A·NCT05967156·30 enrolled

Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients

Unknown status·RRambam Health Care Campus·Phase 4·NCT03271879·128 enrolled

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Recruiting·JJuntendo University·Phase 3·NCT05392764·444 enrolled

Add-on Diuretics in Acute Decompensated Heart Failure

Recruiting·TTanta University·Phase 2·NCT07372040·66 enrolled

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

Completed·SSaint Luke's Health System·Phase 4·NCT03030222·65 enrolled

Canagliflozin in Patients With Acute Decompansted Heart Failure

Completed·OOctober 6 University·Phase 3·NCT05364190·142 enrolled

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04937816·16,746 enrolled

EMPA Acute Heart Failure

Terminated·RRWTH Aachen University·Phase 2·NCT03554200·19 enrolled

Empagliflozin in Acute Heart Failure

Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT05305495·25 enrolled

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT03057951·5,988 enrolled

Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT05139472·8 enrolled

Type 2 Diabetes13 trials

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Completed·MMedanta, The Medicity, India·N/A·NCT02686476·100 enrolled

Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

Completed·IInstitut für Pharmakologie und Präventive Medizin·Phase 3·NCT02752113·101 enrolled

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

Completed·RRWTH Aachen University·Phase 2·NCT03132181·40 enrolled

Show 10 more trials

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01734785·607 enrolled

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04098575·9,571 enrolled

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03993132·26,774 enrolled

Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes

Completed·YYonsei University·N/A·NCT02964572·61 enrolled

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

Withdrawn· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05444153

Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes

Unknown status·UUnity Health Toronto·Phase 4·NCT02998970·97 enrolled

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Recruiting·CCelltrion·Phase 3·NCT07093476·171 enrolled

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT04233801·219 enrolled

Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01984606

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

Active, not recruiting·CCelltrion·Phase 3·NCT06571591·582 enrolled

Diabetes Mellitus8 trials

Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension

Withdrawn·EEMS·Phase 3·NCT04970108

Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus

Recruiting·MMedanta, The Medicity, India·N/A·NCT06095492·200 enrolled

Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions

Completed·RResearch Institute for Complex Problems of Cardiovascular Diseases, Russia·Phase 4·NCT04497792·40 enrolled

Show 5 more trials

Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

Unknown status·EEMS·Phase 3·NCT04603508·240 enrolled

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

Recruiting·EEMS·Phase 3·NCT05028140·480 enrolled

Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

Completed·GGetz Pharma·Phase 4·NCT04665284·244 enrolled

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

Recruiting·EEMS·Phase 3·NCT04670666·270 enrolled

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

Recruiting·EEMS·Phase 3·NCT04602754·228 enrolled

73 more indications

Chronic Kidney Disease5 trials

Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease

Unknown status·MMedical University of Lodz·N/A·NCT04961931·45 enrolled

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT05182840·714 enrolled

Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression

Completed·TTanta University·Phase 2/3·NCT05373680·118 enrolled

Show 2 more trials

Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05465317·62,197 enrolled

Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors

Not yet recruiting·IInstituto de Investigación Biomédica de Salamanca··NCT07348484·300 enrolled

Kidney Disease3 trials

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

Recruiting·MMostafa Bahaa·Phase 2·NCT05638880·60 enrolled

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Not yet recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT07175051·20 enrolled

Empaglifozin in Early Diabetic Kidney Disease

Withdrawn·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT03173963

Type 1 Diabetes Mellitus3 trials

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02702011·48 enrolled

Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01969747·75 enrolled

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02414958·730 enrolled

Hypoglycemia3 trials

Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study

Completed·UUniversity Hospital, Basel, Switzerland·N/A·NCT03200782·12 enrolled

Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes

Withdrawn·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT05174507

Empagliflozin for the Treatment of Postprandial Hypoglycemia

Terminated·UUniversity Hospital, Basel, Switzerland·Phase 3·NCT05036317·40 enrolled

SGLT2 Inhibitors2 trials

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT05057806·30 enrolled

SGLT2 Inhibitors in Glomerular Hyperfiltration

Withdrawn· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT04143581

Metabolic Syndrome2 trials

Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor

Enrolling by invitation·TThe University of Hong Kong·Phase 3·NCT07065357·160 enrolled

Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment

Recruiting·CCollegium Medicum w Bydgoszczy·Phase 3·NCT05905965·200 enrolled

Hyperglycemia2 trials

Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia

Completed·MMedanta, The Medicity, India·N/A·NCT06187285·220 enrolled

Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio

Completed·UUniversity of Diyala··NCT05822674·80 enrolled

Non-Alcoholic Steatohepatitis2 trials

Reducing Non-Alcoholic Steatohepatitis

Enrolling by invitation·MMilitary University Hospital, Prague·N/A·NCT06519448·30 enrolled

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT05282121·90 enrolled

Hypertension2 trials

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension

Completed· Sanofi logo

Sanofi·Phase 2·NCT03462069·41 enrolled

SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

Completed·JJichi Medical University·Phase 4·NCT03050229·174 enrolled

Cardiovascular Disease2 trials

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05102071

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04927858·460,558 enrolled

Kidney Transplant2 trials

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

Terminated·—·Phase 2·NCT04906213·20 enrolled

Empagliflozin Treatment in Kidney Transplant Recipients

Recruiting·VVA Office of Research and Development·Phase 4·NCT06013865·264 enrolled

Autosomal Dominant Polycystic Kidney Disease2 trials

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT05510115·50 enrolled

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

Active, not recruiting·HHannover Medical School·Phase 4·NCT06391450·44 enrolled

Sepsis1 trial

Efficacy of SGLT2 Inhibitors in Adults With Sepsis

Recruiting·HHospital Authority, Hong Kong·N/A·NCT06473844·60 enrolled

Glomerulonephritis1 trial

Empagliflozin in Patients With Glomerulonephritis

Completed·KKasr El Aini Hospital·Phase 3·NCT05283057·50 enrolled

Insulin Sensitivity1 trial

Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT03227484·42 enrolled

Acute Myocardial Infarction1 trial

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Completed·MMedical University of Graz·Phase 3·NCT03087773·476 enrolled

Myocardial Infarction1 trial

EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction

Active, not recruiting·NNHS Greater Glasgow and Clyde·Phase 3·NCT05020704·100 enrolled

Cardiorenal Syndrome Type 11 trial

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Recruiting·—·Phase 2/3·NCT06030843·200 enrolled

Polycystic Ovary Syndrome1 trial

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

Completed·SSINA Health Education and Welfare Trust·Phase 2/3·NCT06140108·70 enrolled

Uric Acid1 trial

SGLT2 Inhibition: Uric Acid Excretion Study

Completed·AAmsterdam UMC, location VUmc·Phase 4·NCT05210517·10 enrolled

Diabetic Neuropathy1 trial

Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

Completed·TTanta University·Phase 1/2·NCT05977465·50 enrolled

Mitral regurgitation1 trial

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

Recruiting·RRehab Werida··NCT07379788·180 enrolled

Cardiovascular1 trial

Cardiovascular Effects of Empagliflozine

Unknown status·TTel Aviv University·N/A·NCT02918591·10 enrolled

Obesity1 trial

The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity

Completed·—·Phase 4·NCT07120828·260 enrolled

NAFLD1 trial

Follow-up of NAFLD Patients With MRI-PDFF

Completed·AAsmaa Abdelfattah Elsayed·Phase 4·NCT04910178·80 enrolled

Cardiomyopathy1 trial

Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age

Not yet recruiting·SSebastiano Lava·Phase 2·NCT06643442·12 enrolled

Pulmonary Arterial Hypertension1 trial

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

Recruiting·CChina National Center for Cardiovascular Diseases·Phase 1·NCT06554301·72 enrolled

Hyponatremia1 trial

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

Completed·UUniversity Hospital, Basel, Switzerland·Phase 2/3·NCT02729766·15 enrolled

Post-Operative Atrial Fibrillation1 trial

Empagliflozin to Prevent Post-Operative Atrial Fibrillation

Unknown status·RRajaie Cardiovascular Medical and Research Center·Phase 3·NCT06124937·492 enrolled

Fasting Conditions1 trial

To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07039890·40 enrolled

Weight loss1 trial

Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors

Withdrawn·UUniversity of Alabama at Birmingham·Phase 2·NCT05885074

Rheumatoid Arthritis1 trial

The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate

Not yet recruiting·TTanta University·Phase 4·NCT06641128·44 enrolled

Acute Kidney Injury1 trial

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

Unknown status·FFayoum University··NCT04853615·800 enrolled

Cirrhosis1 trial

DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis

Recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 4·NCT07322237·400 enrolled

Fatty Liver1 trial

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

Unknown status·GGetz Pharma·Phase 4·NCT04976283·123 enrolled

Liver Disease1 trial

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

Recruiting·JJustin Ryder·Phase 2·NCT06355310·40 enrolled

T2DM1 trial

Glycemic Variability of Combination Therapies in T2DM

Recruiting·JJW Pharmaceutical·Phase 4·NCT07442006·178 enrolled

Antithrombotic1 trial

Antithrombotic Activities of Sotagliflozin vs. Empagliflozin

Active, not recruiting·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT06618976·17 enrolled

Advanced1 trial

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Withdrawn·NNorthwell Health·Phase 4·NCT02768220

COVID-191 trial

Randomised Evaluation of COVID-19 Therapy

Recruiting·UUniversity of Oxford·Phase 3·NCT04381936·70,000 enrolled

Adiposity1 trial

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT02833415·40 enrolled

Cardiac1 trial

Impact of Empaglifozine on Cardiac Ectopic Fat

Completed·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT03118336·56 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Empagliflozin in NODAT

Terminated·RRenJi Hospital·Phase 4·NCT03642184·6 enrolled

Safety and Efficacy1 trial

" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

Unknown status·IInstituto Nacional de Cardiologia Ignacio Chavez·Phase 2/3·NCT05580510·160 enrolled

Injury1 trial

Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI

Unknown status·—·N/A·NCT03591991·128 enrolled

MPA1 trial

Empa/Lina FDC Food Effect Study (Japan)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02815644·22 enrolled

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03464045·344,995 enrolled

Transthyretin Amyloid Cardiomyopathy1 trial

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

Completed·—·Phase 4·NCT05233163·15 enrolled

T1DM1 trial

Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·Phase 3·NCT03979352·28 enrolled

Diabetes1 trial

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

Completed·—··NCT04215536·103,752 enrolled

Treatment1 trial

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03807440·4,083 enrolled

Trial1 trial

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

Recruiting·UUniversity of Pennsylvania·Phase 2·NCT05138575·53 enrolled

Stroke1 trial

EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source

Recruiting·UUniversity of East Anglia·Phase 2/3·NCT06715449·100 enrolled

Diabetic Ketoacidosis1 trial

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02864914·333,580 enrolled

Microvascular Circulation1 trial

Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT02471963·74 enrolled

Albuminuria1 trial

Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)

Withdrawn·SSteno Diabetes Center Copenhagen·Phase 4·NCT03504566

Atrial Fibrillation1 trial

Empagliflozin and Atrial Fibrillation Treatment

Unknown status·—·Phase 4·NCT04583813·400 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease

Not yet recruiting·—·Phase 4·NCT07180745·400 enrolled

Inflammation1 trial

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

Completed·UUniversity of Pisa··NCT04735042·60 enrolled

Urinary Tract Infection1 trial

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03764631·1,502 enrolled

Drug1 trial

Cognitive Protective Effect of Newer Antidiabetic Drugs

Unknown status·—··NCT05347459·100 enrolled

Cardiotoxicity1 trial

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT06844669·7 enrolled

Coronary Artery Disease1 trial

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

Completed·CCHEOL WHAN LEE, M.D., Ph.D·Phase 4·NCT03208465·100 enrolled

Female1 trial

Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02782624·16 enrolled

Transplant Recipient1 trial

Randomized Trial of SGLT2i in Heart Transplant Recipients

Recruiting·VVA Office of Research and Development·Phase 4·NCT06625073·200 enrolled

Schizophrenia1 trial

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

Recruiting·TTanta University·Phase 3·NCT05669742·40 enrolled

Renal Transplant Recipients1 trial

Empagliflozin in Renal Transplant Recipients

Completed·OOslo University Hospital·Phase 4·NCT03157414·49 enrolled

Aortic Valve Replacement1 trial

EMPagliflozin After Aortic Valve Replacement

Active, not recruiting·RRigshospitalet, Denmark·Phase 4·NCT06171802·205 enrolled

Elderly1 trial

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

Unknown status·CCenter for Outcomes Research and Clinical Epidemiology, Italy·Phase 4·NCT04796428·1,167 enrolled

MODY1 trial

Impact of SGLT2 on Glucosuria in HNF1A-MODY

Completed·SSteno Diabetes Center Copenhagen·N/A·NCT05417646·21 enrolled

Unspecified3 trials

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Completed·—·N/A·NCT06065280·80 enrolled

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT02792400·24 enrolled

Pharmacological Reduction of Right Ventricular Enlargement

Completed·—·Phase 3·NCT04345796·56 enrolled

Regulatory

FDA Approval Timeline[5]

Aug 1, 2014

JARDIANCE

NDA NDA204629

Sources

References

[1]
ClinicalTrials.gov — 416 trial records for Empagliflozin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Jardiance drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Empagliflozin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Empagliflozin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA204629). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Jardiance. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Sodium/glucose Cotransporter 2 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

Patent Landscape[6]

Patent Cliff

Oct 15, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7713938*PEDOct 15, 2027

7579449*PEDFeb 1, 2029

12115179Feb 11, 2030

8551957*PEDApr 14, 2030

12115179*PEDAug 11, 2030

11 more patents

12527810*PEDOct 22, 2033

11813275Apr 3, 2034

12263153Apr 3, 2034

9949997May 17, 2034

11833166*PEDOct 3, 2034

10258637*PEDOct 3, 2034

11813275*PEDOct 3, 2034

11090323*PEDOct 3, 2034

12433906*PEDOct 3, 2034

9949997*PEDNov 17, 2034

9949998*PEDDec 11, 2034

Jardiance

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Empagliflozin55 trials

Type 2 Diabetes Mellitus17 trials

Heart Failure14 trials

Type 2 Diabetes13 trials

Diabetes Mellitus8 trials

Chronic Kidney Disease5 trials

Kidney Disease3 trials

Type 1 Diabetes Mellitus3 trials

Hypoglycemia3 trials

SGLT2 Inhibitors2 trials

Metabolic Syndrome2 trials

Hyperglycemia2 trials

Non-Alcoholic Steatohepatitis2 trials

Hypertension2 trials

Cardiovascular Disease2 trials

Kidney Transplant2 trials

Autosomal Dominant Polycystic Kidney Disease2 trials

Sepsis1 trial

Glomerulonephritis1 trial

Insulin Sensitivity1 trial

Acute Myocardial Infarction1 trial

Myocardial Infarction1 trial

Cardiorenal Syndrome Type 11 trial

Polycystic Ovary Syndrome1 trial

Uric Acid1 trial

Diabetic Neuropathy1 trial

Mitral regurgitation1 trial

Cardiovascular1 trial

Obesity1 trial

NAFLD1 trial

Cardiomyopathy1 trial

Pulmonary Arterial Hypertension1 trial

Hyponatremia1 trial

Post-Operative Atrial Fibrillation1 trial

Fasting Conditions1 trial

Weight loss1 trial

Rheumatoid Arthritis1 trial

Acute Kidney Injury1 trial

Cirrhosis1 trial

Fatty Liver1 trial

Liver Disease1 trial

T2DM1 trial

Antithrombotic1 trial

Advanced1 trial

COVID-191 trial

Adiposity1 trial

Cardiac1 trial

Efficacy and Safety1 trial

Safety and Efficacy1 trial

Injury1 trial

MPA1 trial

Medication1 trial

Type 1 Diabetes1 trial

Malignancies1 trial

Transthyretin Amyloid Cardiomyopathy1 trial

T1DM1 trial

Diabetes1 trial

Treatment1 trial

Trial1 trial

Stroke1 trial

Diabetic Ketoacidosis1 trial

Microvascular Circulation1 trial

Albuminuria1 trial

Atrial Fibrillation1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Inflammation1 trial

Urinary Tract Infection1 trial

Drug1 trial

Cardiotoxicity1 trial

Coronary Artery Disease1 trial

Female1 trial

Transplant Recipient1 trial

Schizophrenia1 trial